Does Rallies show 13F holders for ESPR?

Yes. Rallies tracks hedge fund and 13F ownership data for ESPR, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ESPR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ESPR. It does not provide personalized investment advice.

ESPR (Esperion Therapeutics, Inc.) Stock Analysis - Hedge Fund Holdings

Esperion Therapeutics, Inc. (ESPR) is a publicly traded Healthcare sector company. As of May 21, 2026, ESPR trades at $3.13 with a market cap of $805.76M and a P/E ratio of -225901000000000000.00. ESPR moved +0.16% today. Year to date, ESPR is -17.85%; over the trailing twelve months it is +244.45%. Its 52-week range spans $0.69 to $4.18. Analyst consensus is neutral with an average price target of $2.92. Rallies surfaces ESPR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ESPR stock?

Hedge funds tracked by Rallies that own ESPR include Orbimed Advisors, Centerbook Partners, Pentwater Capital, and Polen Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Esperion Therapeutics, Inc..

ESPR Key Metrics

Key financial metrics for ESPR
Metric	Value
Price	$3.13
Market Cap	$805.76M
P/E Ratio	-225901000000000000.00
EPS	$-0.00
Dividend Yield	0.00%
52-Week High	$4.18
52-Week Low	$0.69
Volume	2.14K
Avg Volume	0
Revenue (TTM)	$418.24M
Net Income	$-7.42M
Gross Margin	0.00%

Top Hedge Funds Holding ESPR

Orbimed Advisors holds 10.57M shares of ESPR, changed +77.19% as of Mar 31, 2026.
Centerbook Partners holds 1.31M shares of ESPR, changed -58.03% as of Dec 31, 2024.
Pentwater Capital holds 181.29K shares of ESPR, changed +0.00% as of Sep 30, 2025.
Polen Capital holds 116.29K shares of ESPR, changed +0.00% as of Dec 31, 2025.

Latest ESPR News

Esperion Sale at $3.16 Per Share Includes $100M CVRs, Faces Rights Probe — May 4, 2026
ARCHIMED to Buy Esperion for $1.1B at $3.16 per Share with $100M Milestones — May 1, 2026
Bempedoic Acid Cuts Ischemic Stroke Risk 22%, Shows Similar MACE Benefit in Autoimmune/Inflammatory Disease Patients — Mar 30, 2026
Esperion Reports 144% Revenue Surge to $168.4M, Agrees to Acquire Corstasis — Mar 10, 2026
Esperion to Acquire Corstasis for $75M, Adding FDA-Approved Nasal Diuretic — Mar 4, 2026

Recent ESPR Insider Trades

Looker Benjamin sold 5.71K (~$15.43K) on Mar 17, 2026.
Koenig Sheldon L. sold 25.58K (~$69.55K) on Mar 17, 2026.
Halladay Benjamin sold 6.42K (~$17.38K) on Mar 17, 2026.

ESPR Analyst Consensus

7 analysts cover ESPR: 0 strong buy, 0 buy, 6 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $2.92.

Common questions about ESPR

Who owns ESPR stock?: Hedge funds tracked by Rallies that own ESPR include Orbimed Advisors, Centerbook Partners, Pentwater Capital, and Polen Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Esperion Therapeutics, Inc..
Does Rallies show 13F holders for ESPR?: Yes. Rallies tracks hedge fund and 13F ownership data for ESPR, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ESPR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ESPR. It does not provide personalized investment advice.